BACKGROUND: We analyzed the effect of peri-transplant prophylaxis on the epidemiology of bacteremia in a 12-year contemporary cohort of allogeneic HSCT recipients at our center. METHODS: This was an observational study of 1052 consecutive adult HSCT from 2000 to 2011. Formal prophylaxis with vancomycin only, fluoroquinolone (FQ) only, or vancomycin + FQ was implemented in 2006. The cumulative incidence of day 100 bacteremia was compared between the Early Period (2000-2005) and the Recent Period (2006-2011). Predictors for pre-engraftment bacteremia were analyzed with Cox-proportional hazard models in a subcohort of 821 HSCT who received myeloablative or reduced intensity conditioning (MA/RIC). RESULTS: The incidence of bacteremia decreased in the Recent Period (32% vs 27%; P = 0.002), whereas the rates of resistance in gram-negative rods (GNR) and vancomycin-resistant enterococci (VRE) were similar between the two Periods (P values are not statistically significant.) In multivariate analyses, prophylaxis with vancomycin only or vancomycin + FQ was protective (HR = 0.5; CI = 0.30-0.72) and (HR = 0.3; CI = 0.12-0.52, P < 0.01). Vancomycin or vancomycin + FQ eliminated viridans streptococcal bacteremia (VSB); vancomycin + FQ decreased GNR bacteremia (HR = 0.35; CI = 0.15-0.85). CONCLUSIONS: Vancomycin-based prophylaxis peri-transplant in MA/RIC HSCT was associated with elimination of VSB and may be considered at centers with high incidence of this infection.
BACKGROUND: We analyzed the effect of peri-transplant prophylaxis on the epidemiology of bacteremia in a 12-year contemporary cohort of allogeneic HSCT recipients at our center. METHODS: This was an observational study of 1052 consecutive adult HSCT from 2000 to 2011. Formal prophylaxis with vancomycin only, fluoroquinolone (FQ) only, or vancomycin + FQ was implemented in 2006. The cumulative incidence of day 100 bacteremia was compared between the Early Period (2000-2005) and the Recent Period (2006-2011). Predictors for pre-engraftment bacteremia were analyzed with Cox-proportional hazard models in a subcohort of 821 HSCT who received myeloablative or reduced intensity conditioning (MA/RIC). RESULTS: The incidence of bacteremia decreased in the Recent Period (32% vs 27%; P = 0.002), whereas the rates of resistance in gram-negative rods (GNR) and vancomycin-resistant enterococci (VRE) were similar between the two Periods (P values are not statistically significant.) In multivariate analyses, prophylaxis with vancomycin only or vancomycin + FQ was protective (HR = 0.5; CI = 0.30-0.72) and (HR = 0.3; CI = 0.12-0.52, P < 0.01). Vancomycin or vancomycin + FQ eliminated viridans streptococcal bacteremia (VSB); vancomycin + FQ decreased GNR bacteremia (HR = 0.35; CI = 0.15-0.85). CONCLUSIONS:Vancomycin-based prophylaxis peri-transplant in MA/RIC HSCT was associated with elimination of VSB and may be considered at centers with high incidence of this infection.
Authors: Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh Journal: Biol Blood Marrow Transplant Date: 2009-10 Impact factor: 5.742
Authors: David Landman; Elizabeth Babu; Neha Shah; Paul Kelly; Olafisoye Olawole; Martin Bäcker; Simona Bratu; John Quale Journal: J Antimicrob Chemother Date: 2012-02-29 Impact factor: 5.790
Authors: Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard Journal: Clin Infect Dis Date: 2011-01-04 Impact factor: 9.079
Authors: Mini Kamboj; Dick Chung; Susan K Seo; Eric G Pamer; Kent A Sepkowitz; Ann A Jakubowski; Genovefa Papanicolaou Journal: Biol Blood Marrow Transplant Date: 2010-05-26 Impact factor: 5.742
Authors: Ying Taur; Joao B Xavier; Lauren Lipuma; Carles Ubeda; Jenna Goldberg; Asia Gobourne; Yeon Joo Lee; Krista A Dubin; Nicholas D Socci; Agnes Viale; Miguel-Angel Perales; Robert R Jenq; Marcel R M van den Brink; Eric G Pamer Journal: Clin Infect Dis Date: 2012-06-20 Impact factor: 9.079
Authors: Jan Vydra; Ryan M Shanley; Ige George; Celalettin Ustun; Angela R Smith; Daniel J Weisdorf; Jo-Anne H Young Journal: Clin Infect Dis Date: 2012-06-12 Impact factor: 9.079
Authors: Lindsey Robert Baden; William Bensinger; Michael Angarone; Corey Casper; Erik R Dubberke; Alison G Freifeld; Ramiro Garzon; John N Greene; John P Greer; James I Ito; Judith E Karp; Daniel R Kaul; Earl King; Emily Mackler; Kieren A Marr; Jose G Montoya; Ashley Morris-Engemann; Peter G Pappas; Ken Rolston; Brahm Segal; Susan K Seo; Sankar Swaminathan; Maoko Naganuma; Dorothy A Shead Journal: J Natl Compr Canc Netw Date: 2012-11-01 Impact factor: 11.908
Authors: Mini Kamboj; Nina Cohen; Yao-Ting Huang; Marina Kerpelev; Ann Jakubowski; Kent A Sepkowitz; Genovefa A Papanicolaou; Susan K Seo Journal: Biol Blood Marrow Transplant Date: 2018-11-15 Impact factor: 5.742
Authors: Yao-Ting Huang; Dionysios Neofytos; Julia Foldi; Seong Jin Kim; Molly Maloy; Dick Chung; Hugo Castro-Malaspina; Sergio A Giralt; Esperanza Papadopoulos; Miguel-Angel Perales; Ann A Jakubowski; Genovefa A Papanicolaou Journal: Biol Blood Marrow Transplant Date: 2016-05-10 Impact factor: 5.742
Authors: Marcel R M van den Brink; Robert R Jenq; Yusuke Shono; Melissa D Docampo; Jonathan U Peled; Suelen M Perobelli; Enrico Velardi; Jennifer J Tsai; Ann E Slingerland; Odette M Smith; Lauren F Young; Jyotsna Gupta; Sophia R Lieberman; Hillary V Jay; Katya F Ahr; Kori A Porosnicu Rodriguez; Ke Xu; Marco Calarfiore; Hendrik Poeck; Silvia Caballero; Sean M Devlin; Franck Rapaport; Jarrod A Dudakov; Alan M Hanash; Boglarka Gyurkocza; George F Murphy; Camilla Gomes; Chen Liu; Eli L Moss; Shannon B Falconer; Ami S Bhatt; Ying Taur; Eric G Pamer Journal: Sci Transl Med Date: 2016-05-18 Impact factor: 17.956